Acousia Therapeutics is a Clinical Phase 2 stage biotech company based in Tübingen, Germany, dedicated to the effective prevention and treatment of different hearing loss.

Hearing loss is a global pandemic with no drug treatments available. We pursue a unique target preferentially expressed in the sensory cells of the inner ear: Our most advanced program ACOU085 is a first-in-class, etiology-agnostic otoprotective small molecule activator of Kv7.4 potassium channels for local delivery through standard transtympanic injection. We are expecting to finish enrolment of testicular cancer patients undergoing cisplatin chemotherapy in our PROHEAR Ph2a clinical trial by Q4 2025 with topline readout planned for Q1 2026. Our second program ACOU082 is in preclinical development, but developed for oral administration in chronic/progressive hearing indications such as age-related hearing loss, with combined immediate enhancement of hearing function and longterm reduction of hearing loss progression.